Currently, the survival rate for
breast cancer is more than 90%, but once the
cancer cells metastasize to distal organs, the survival rate is dramatically reduced, to less than 30%.
Triple-negative breast cancer accounts for 15-20% of all breast
cancers.
Triple-negative breast cancer (TNBC) is associated with poor prognostic and diagnostic outcomes due to the limiting therapeutic strategies, relative to non-TNBC breast
cancers. Therefore, the development of targeted
therapy for TNBC
metastasis remains an urgent issue. In this study, high Carboxyl-terminal modulator
protein (
CTMP) is significantly associated with recurrence and disease-free survival rate in TNBC patients. Overexpression of
CTMP promotes migration and invasion abilities in BT549 cells. Down-regulating of
CTMP expression inhibits migration and invasion abilities in MDA-MB-231 cells. In vivo inoculation of high-
CTMP cells enhances distant
metastasis in mice. The
metastasis incidence rate is decreased in mice injected with
CTMP-downregulating MDA-MB-231 cells. Gene expression microarray analysis indicates the Akt-dependent pathway is significantly enhanced in
CTMP overexpressing cells compared to the parental cells. Blocking Akt activation via Akt inhibitor treatment or co-expression of the dominant-negative form of Akt
proteins successfully abolishes the
CTMP mediating invasion in TNBC cells. Our findings suggest that
CTMP is a potential diagnostic marker for recurrence and poor disease-free survival in TNBC patients.
CTMP promotes TNBC
metastasis via the Akt-activation-dependent pathway.